Cannabidiol and pain
- 2 July 2024
- book chapter
- Published by Elsevier
- Vol. 177, 29-63
Abstract
No abstract availableKeywords
This publication has 129 references indexed in Scilit:
- Oral capsules of tetra‐hydro‐cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatmentEuropean journal of pain, 2023
- Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory painPsychopharmacology, 2018
- Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritisEuropean journal of pain, 2015
- Cannabinoids for Medical UseJAMA, 2015
- The association between comorbidities and pain, physical function and quality of life following hip and knee arthroplastyRheumatology International, 2015
- A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatmentEuropean journal of pain, 2014
- Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviourPsychopharmacology, 2011
- Cannabinoid‐mediated antinociception is enhanced in rat osteoarthritic kneesArthritis & Rheumatism, 2007
- Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat pawNaunyn-Schmiedeberg's Archives of Pharmacology, 2004
- Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cellsGlia, 2000